AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Sanara MedTech Q2 net rev up 28% YoY, net loss narrows to $2mln.
ByAinvest
Wednesday, Aug 13, 2025 7:04 am ET1min read
• Sanara MedTech's Q2 net revenue up 28% YoY to $25.8mln • Net loss of $2.0mln, compared to $3.5mln in Q2 2024 • Adjusted EBITDA at $2.7mln, up from $0.6mln in Q2 2024 • Announced process to evaluate strategic alternatives for Tissue Health Plus subsidiary • Net revenue increased 27% YoY in first six months of 2025
Sanara MedTech Inc. (Nasdaq: SMTI) reported robust financial results for the second quarter of 2025, with net revenue surging 28% year-over-year (YoY) to $25.8 million. The company's Sanara Surgical segment played a pivotal role in this growth, generating $0.5 million in net income and $4.7 million in Segment Adjusted EBITDA. This segment's performance was bolstered by strong sales of products such as CellerateRX Surgical and BIASURGE, along with improved gross margins to 93%.Despite the positive performance in the surgical segment, Sanara MedTech faced significant challenges in its Tissue Health Plus (THP) subsidiary. The THP segment reported a net loss of $2.5 million in Q2 2025, contributing to an overall net loss of $2.0 million for the quarter, compared to $3.5 million in Q2 2024. The company has announced a formal process to evaluate strategic alternatives for THP, with a projected cash investment of $5.5 to $6.5 million in the second half of 2025.
Operating expenses increased by 14% YoY to $23.9 million, primarily driven by expanded sales and marketing investments and THP-related costs. However, the company's operating loss narrowed significantly to just $31,000 from $2.9 million in Q2 2024, indicating improved operational leverage. Cash flow from operations strengthened to $2.7 million in Q2, up from $1.4 million in Q2 2024.
The company's debt position has increased to $44.2 million from $30.7 million at year-end 2024, suggesting higher financial leverage to fund growth and THP initiatives. The contrasting performance between the surgical and THP segments presents a complex picture, with the market closely monitoring Sanara MedTech's ability to address the THP challenges while maintaining momentum in its core surgical business.
References:
[1] https://www.stocktitan.net/news/SMTI/sanara-med-tech-inc-reports-second-quarter-2025-financial-results-p5lwnpehloog.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet